Megan K Herbert1, Ger J M Pruijn. 1. Department of Biomolecular Chemistry, Radboud Institute for Molecular Life Sciences and Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to discuss recent advances in serological testing for sporadic inclusion body myositis (sIBM) and to provide a review of their diagnostic utility and disease-specificity of auto-antibodies in sIBM. RECENT FINDINGS: The identification, prevalence and diagnostic utility of a new auto-antibody targeting cytosolic 5'-nucleotidase 1A (cN-1A) in the serum of sIBM patients have recently been published. These studies have shown that anti-cN-1A auto-antibodies have diagnostic utility for differentiating sIBM from other forms of myositis and from other neuromuscular diseases. Anti-cN-1A-positive patient sera are directed to multiple epitopes of cN-1A and contain, in addition to IgG, IgA and IgM, anti-cN-1A auto-antibodies. Recent studies have also shown a relatively high prevalence of these auto-antibodies in sera form Sjögren's syndrome and systemic lupus erythematosus patients. SUMMARY: The recent discovery of auto-antibodies to cN-1A provides a serological tool to aid the differentiation between inflammatory myopathies and supports the idea that apart from degeneration, an adaptive immune response may also play a role in sIBM pathophysiology. Future research will need to focus on standardization of methods to detect these auto-antibodies in order to further explore their specificity and diagnostic utility for sIBM.
PURPOSE OF REVIEW: The purpose of this article is to discuss recent advances in serological testing for sporadic inclusion body myositis (sIBM) and to provide a review of their diagnostic utility and disease-specificity of auto-antibodies in sIBM. RECENT FINDINGS: The identification, prevalence and diagnostic utility of a new auto-antibody targeting cytosolic 5'-nucleotidase 1A (cN-1A) in the serum of sIBM patients have recently been published. These studies have shown that anti-cN-1A auto-antibodies have diagnostic utility for differentiating sIBM from other forms of myositis and from other neuromuscular diseases. Anti-cN-1A-positive patient sera are directed to multiple epitopes of cN-1A and contain, in addition to IgG, IgA and IgM, anti-cN-1A auto-antibodies. Recent studies have also shown a relatively high prevalence of these auto-antibodies in sera form Sjögren's syndrome and systemic lupus erythematosuspatients. SUMMARY: The recent discovery of auto-antibodies to cN-1A provides a serological tool to aid the differentiation between inflammatory myopathies and supports the idea that apart from degeneration, an adaptive immune response may also play a role in sIBM pathophysiology. Future research will need to focus on standardization of methods to detect these auto-antibodies in order to further explore their specificity and diagnostic utility for sIBM.
Authors: Sabine L Kramp; Dmitry Karayev; Guo Shen; Allan L Metzger; Robert I Morris; Eugene Karayev; Yvonne Lam; Richard M Kazdan; Ger J M Pruijn; Sandra Saschenbrecker; Cornelia Dähnrich; Wolfgang Schlumberger Journal: Auto Immun Highlights Date: 2016-11-17
Authors: J B Lilleker; A Rietveld; S R Pye; K Mariampillai; O Benveniste; M T J Peeters; J A L Miller; M G Hanna; P M Machado; M J Parton; K R Gheorghe; U A Badrising; I E Lundberg; S Sacconi; M K Herbert; N J McHugh; B R F Lecky; C Brierley; D Hilton-Jones; J A Lamb; M E Roberts; R G Cooper; C G J Saris; G J M Pruijn; H Chinoy; B G M van Engelen Journal: Ann Rheum Dis Date: 2017-01-25 Impact factor: 19.103
Authors: Anke Rietveld; Luuk L van den Hoogen; Nicola Bizzaro; Sofie L M Blokland; Cornelia Dähnrich; Jacques-Eric Gottenberg; Gunnar Houen; Nora Johannsen; Thomas Mandl; Alain Meyer; Christoffer T Nielsen; Peter Olsson; Joel van Roon; Wolfgang Schlumberger; Baziel G M van Engelen; Christiaan G J Saris; Ger J M Pruijn Journal: Front Immunol Date: 2018-06-05 Impact factor: 7.561